Prosecution Insights
Prosecution Insights
37 pending office actions • 26 art units • 35 examiners • 0 of 37 (0%) have an AI response strategy ready • 75 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 37 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 37 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §103 only | 20 (54%) |
| §102 only | 4 (11%) |
| §112 only | 2 (5%) |
| Double-patenting + other | 1 (3%) |
| No statute on record | 9 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 2 | 63.5% | +38.8% |
| BRADLEY, CHRISTINA | 2 | 62.7% | +33.2% |
| BALLARD, KIMBERLY | 1 | 53.7% | +48.8% |
| HEIN, DEVIN C | 1 | 45.8% | +29.9% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| FORD, VANESSA L | 1 | 40.1% | +38.3% |
| LUK, EMMANUEL S | 1 | 71.3% | +26.3% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.1% |
| TANG, JIANMING | 1 | — | — |
| HOLLAND, PAUL J | 1 | 57.5% | +64.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19080665 | System for Medicinal Supply Monitoring and Management for Pooled Medicinal Product Across Studies | HEIN, DEVIN C | 75d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19346638 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | BALLARD, KIMBERLY | 26d overdue |
| 18548640 | REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE | HOLLAND, PAUL J | 19d overdue |
| 17785279 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | BRADLEY, CHRISTINA | 4d overdue |
| 17785287 | STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | BRADLEY, CHRISTINA | 4d overdue |
| 18405772 | HIGH CONCENTRATION SOLUTION ANTIBODY FORMULATIONS COMPRISING ANTI-IL-23p19 ANTIBODIES | FORD, VANESSA L | 3d overdue |
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | VANHORN, ABIGAIL LOUISE | 6d |
| 18557487 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | YOUNGBLOOD, WILLIAM JUSTIN | 14d |
| 17784718 | INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | YOUNGBLOOD, WILLIAM JUSTIN | 14d |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1629 | 2 |
| 1671 | 2 |
| 1619 | 2 |
| 1627 | 2 |
| 1647 | 2 |
| 3783 | 2 |
| 1621 | 2 |
| 1626 | 2 |
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19346638 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | BALLARD, KIMBERLY | 1675 | Other | Non-Final OA | 26d overdue | Pending | Oct 01, 2025 |
| 19080665 | System for Medicinal Supply Monitoring and Management for Pooled Medicinal Product Across Studies | HEIN, DEVIN C | 3686 | §101 | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 18882177 | STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | PRIEST, JESSICA MARIE | 1642 | §103 | Non-Final OA | 47d | Pending | Sep 11, 2024 |
| 18405772 | HIGH CONCENTRATION SOLUTION ANTIBODY FORMULATIONS COMPRISING ANTI-IL-23p19 ANTIBODIES | FORD, VANESSA L | 1674 | Other | Non-Final OA | 3d overdue | Pending | Jan 05, 2024 |
| 18557487 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §112 | Non-Final OA | 14d | Pending | Oct 26, 2023 |
| 18484485 | BLOW-FILL SEALING METHOD FOR FILLING AND PACKAGING | LUK, EMMANUEL S | 1744 | §103 | Non-Final OA | 19d | Pending | Oct 11, 2023 |
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | VANHORN, ABIGAIL LOUISE | 1636 | Other | Non-Final OA | 6d | Pending | Oct 03, 2023 |
| 18550348 | A CLOSED-SYSTEM UPSTREAM MANUFACTURING PROCESS FOR DENGUE VIRUS PRODUCTION | TANG, JIANMING | 1671 | §103 | Non-Final OA | 4d overdue | Pending | Sep 13, 2023 |
| 18548640 | REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | 19d overdue | Pending | Sep 01, 2023 |
| 18263277 | LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES | MORGAN, BAILEY MICHELLE | 1645 | Other | Non-Final OA | 9d overdue | Pending | Jul 27, 2023 |
| 18348787 | DENSIFIED CO-PRECIPITATED MATERIALS ISOLATED BY THIN FILM EVAPORATION | GOTFREDSON, GAREN | 1619 | §103 | Non-Final OA | 5d overdue | Pending | Jul 07, 2023 |
| 18258903 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | NESTOR, DONNA MICHELLE | 1627 | Other | Final Rejection | 33d | Pending | Jun 22, 2023 |
| 18258397 | IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | 15d overdue | Pending | Jun 20, 2023 |
| 18256943 | MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 15d overdue | Pending | Jun 12, 2023 |
| 18256997 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | JOHNSON, CHRISTOPHER LINDSAY | 1691 | Other | Non-Final OA | 9d | Pending | Jun 12, 2023 |
| 18317377 | SYRINGES AND INJECTORS WITH CAPACITIVE SENSING AND METHODS OF MAKING AND USING SAME | SHAH, NILAY J | 3783 | §103 | Non-Final OA | 5d | Pending | May 15, 2023 |
| 18310238 | Niraparib Compositions | MOU, LIYUAN | 1628 | §103 | Non-Final OA | 55d | Pending | May 01, 2023 |
| 18250429 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | BELL, SARA ELIZABETH | 1625 | DPOther | Final Rejection | 62d | Pending | Apr 25, 2023 |
| 18250404 | METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES WITH AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | OTTON, ALICIA L | 1699 | §103 | Non-Final OA | 17d overdue | Pending | Apr 25, 2023 |
| 18246467 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF | CHHAY, BONIRATH | 1645 | Other | Non-Final OA | 43d overdue | Pending | Mar 23, 2023 |
| 18015671 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | O DELL, DAVID K | 1621 | §103 | Non-Final OA | 16d overdue | Pending | Jan 11, 2023 |
| 18009310 | 5-OXOPYRROLIDINE-3-CARBOXAMIDES AS NAV1.8 INHIBITORS | FERGUSON, JALISA HOLMES | 1626 | §102 | Final Rejection | 77d | Pending | Dec 08, 2022 |
| 18007776 | RIPK1 INHIBITORS AND METHODS OF USE | HERNANDEZ, JACKSON J | 1627 | §102 | Final Rejection | 36d overdue | Pending | Dec 02, 2022 |
| 17920876 | MODULAR BLENDER AND METHOD OF USING SAME | SORKIN, DAVID L | 1774 | §103 | Non-Final OA | 26d | Pending | Oct 24, 2022 |
| 17916664 | AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | 60d | Pending | Oct 03, 2022 |
| 17798754 | ALTERNATIVE CANNULA CONFIGURATIONS TO CONTROL FLUID DISTRIBUTION IN TISSUE | BOUCHELLE, LAURA A | 3783 | §103 | Non-Final OA | 38d overdue | Pending | Aug 10, 2022 |
| 17817382 | HPV VACCINE | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | 16d overdue | Pending | Aug 04, 2022 |
| 17789374 | ARGINASE INHIBITORS AND METHODS OF USE | WILSON, JERICA KATLYNN | 1621 | §102 | Non-Final OA | 66d overdue | Pending | Jun 27, 2022 |
| 17785750 | NON-INVASIVE CONTINUOUS CAPACITANCE LEVEL DETECTOR | DEVITO, ALEX T | 2855 | §103 | Non-Final OA | 89d overdue | Pending | Jun 15, 2022 |
| 17785772 | STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103 | Final Rejection | 29d | Pending | Jun 15, 2022 |
| 17785279 | STAPLED LACTAM CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | BRADLEY, CHRISTINA | 1654 | Other | Final Rejection | 4d overdue | Pending | Jun 14, 2022 |
| 17785287 | STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS | BRADLEY, CHRISTINA | 1654 | §103 | Final Rejection | 4d overdue | Pending | Jun 14, 2022 |
| 17784718 | INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §103 | Non-Final OA | 14d | Pending | Jun 13, 2022 |
| 17783938 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | KONOPKA, CATHERINE ANNE | 1635 | Other | Final Rejection | 42d overdue | Pending | Jun 09, 2022 |
| 17779427 | IN VITRO CELL BASED POTENCY ASSAY | TAKENAKA, RISA | 1632 | §103 | Final Rejection | 9d | Pending | May 24, 2022 |
| 17614865 | AN IMMUNOGENIC SEROTYPE 35B PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE AND CONJUGATION PROCESS FOR MAKING THE SAME | KOLKER, DANIEL E | 1645 | §103 | Final Rejection | 139d overdue | Pending | Nov 29, 2021 |
| 17093833 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | PATEL, SAGAR S | 1626 | §102 | Non-Final OA | 4d overdue | Pending | Nov 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial